Skip to Main Content

Paper Details

Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial.
J Am Coll Cardiol
39
2020
Acute Coronary Syndrome, Acute Coronary Syndromes, Alirocumab, Cholesterol, LDL-C, Patients, acute coronary syndrome, apolipoprotein, cholesterol, low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, patient, patients, statin, subtilisin-kexin type 9
Author NameAffiliation
Deepak L BhattBrigham and Women's Hospital, Harvard Medical School
Robert A HarringtonStanford University Medical Center
Kenneth W MahaffeyStanford University Medical Center
Matthew T Roe
Renato D LopesDuke Clinical Research Institute, Duke University Medical Center, Duke University School of Medicine
  • 1 - 5

Datasets

Release 1.2